Year None202320222021 May 11, 2023 Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update March 31, 2023 Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update January 31, 2023 Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site January 9, 2023 Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
March 31, 2023 Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
January 31, 2023 Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
January 9, 2023 Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer